COVID-19, and specifically long COVID, is associated with an increased risk of cardiovascular disease. Listen as Amitava Banerjee describes his work in this area, especially the STIMULATE-ICP trial, which looks at long COVID’s physiological and social impact. Find out about what the NHS is doing to tackle COVID-19 and its associated cardiovascular and metabolic abnormalities.